trial

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCTId NCT00307203
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 51 (actual)
Sponsored by National Institute on Drug Abuse (NIDA)
Primary completion 2004-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
51 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
1998-08
Primary completion
2004-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
bupropion SRCognitive Behavioral Group TherapyNicotine replacement therapy

Sponsors

National Institute on Drug Abuse (NIDA)Lead Sponsor

Investigators

1
A. Eden Evins, MD, MPHPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
51
Phase
PHASE4
Primary Completion Date
2004-02
Status
COMPLETED
relationships
The graph out of here
drug
bupropion SR
drug
Cognitive Behavioral Group Therapy
drug
Nicotine replacement therapy
drug
lead_sponsor
National Institute on Drug Abuse (NIDA)
company
indication
Psychotic Disorders
indication
Tobacco Use Disorder
indication
Psychotic Disorders
indication
investigator
A. Eden Evins, MD, MPH
person